Article Text

Download PDFPDF

Correction: Study protocol for the POPART study – Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial

Statistics from

Murphy MC, Galligan M, Molloy B, et al. Study protocol for the POPART study—Prophylactic Oropharyngeal surfactant for Preterm infants: A Randomised Trial. BMJ Open 2020;10:e035994. doi: 10.1136/bmjopen-2019-035994

The authors want to alert readers to the following update in the published version. The funding statement of this article is updated with the below statement:

Chiesi Farmaceutici, manufacturers of poractant alfa (Curosurf), supply the study drug free of charge; they had no role in study design; have no role in study conduct; and will have no role in data collection, analysis or interpretation. Further, they will have no role in the decision to present, publish or otherwise report results.

Madeleine Murphy is the recipient of a Clinical Research Fellowship by the National Children’s Research Centre, Dublin (R17637).

Paediatric Clinical Research Infrastructure Network (PedCRIN), a Project of the European Union Horizon 2020 programme designed to support the extension of clinical drug trials in children throughout Europe, also support the study.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles